These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35676339)

  • 1. Splicing analyses for variants in MMR genes: best practice recommendations from the European Mismatch Repair Working Group.
    Morak M; Pineda M; Martins A; Gaildrat P; Tubeuf H; Drouet A; Gómez C; Dámaso E; Schaefer K; Steinke-Lange V; Koehler U; Laner A; Hauchard J; Chauris K; Holinski-Feder E; Capellá G
    Eur J Hum Genet; 2022 Sep; 30(9):1051-1059. PubMed ID: 35676339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays.
    Thompson BA; Martins A; Spurdle AB
    Clin Genet; 2015 Feb; 87(2):100-8. PubMed ID: 24989436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes.
    Morak M; Schaefer K; Steinke-Lange V; Koehler U; Keinath S; Massdorf T; Mauracher B; Rahner N; Bailey J; Kling C; Haeusser T; Laner A; Holinski-Feder E
    Eur J Hum Genet; 2019 Dec; 27(12):1808-1820. PubMed ID: 31332305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing analysis for exonic and intronic mismatch repair gene variants associated with Lynch syndrome confirms high concordance between minigene assays and patient RNA analyses.
    van der Klift HM; Jansen AM; van der Steenstraten N; Bik EC; Tops CM; Devilee P; Wijnen JT
    Mol Genet Genomic Med; 2015 Jul; 3(4):327-45. PubMed ID: 26247049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants.
    Borràs E; Pineda M; Cadiñanos J; Del Valle J; Brieger A; Hinrichsen I; Cabanillas R; Navarro M; Brunet J; Sanjuan X; Musulen E; van der Klift H; Lázaro C; Plotz G; Blanco I; Capellá G
    J Med Genet; 2013 Aug; 50(8):552-63. PubMed ID: 23709753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative analysis of hereditary nonpolyposis colorectal cancer: the contribution of allele-specific expression and other assays to diagnostic algorithms.
    De Lellis L; Aceto GM; Curia MC; Catalano T; Mammarella S; Veschi S; Fantini F; Battista P; Stigliano V; Messerini L; Mareni C; Sala P; Bertario L; Radice P; Cama A
    PLoS One; 2013; 8(11):e81194. PubMed ID: 24278394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splicing analysis of 24 potential spliceogenic variants in MMR genes and clinical interpretation based on refined ACMG/AMP criteria.
    Bouras A; Lefol C; Ruano E; Grand-Masson C; Auclair-Perrossier J; Wang Q
    Hum Mol Genet; 2024 May; 33(10):850-859. PubMed ID: 38311346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene.
    Drost M; Koppejan H; de Wind N
    Hum Mutat; 2013 Nov; 34(11):1477-80. PubMed ID: 24027009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new strategy to screen MMR genes in Lynch Syndrome: HA-CAE, MLPA and RT-PCR.
    Perez-Cabornero L; Velasco E; Infante M; Sanz D; Lastra E; Hernández L; Miner C; Duran M
    Eur J Cancer; 2009 May; 45(8):1485-93. PubMed ID: 19250818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of genetic variants for clinical management of familial colorectal tumors.
    Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
    BMC Med Genet; 2018 Feb; 19(1):26. PubMed ID: 29458332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional testing strategy for coding genetic variants of unclear significance in MLH1 in Lynch syndrome diagnosis.
    Hinrichsen I; Schäfer D; Langer D; Köger N; Wittmann M; Aretz S; Steinke V; Holzapfel S; Trojan J; König R; Zeuzem S; Brieger A; Plotz G
    Carcinogenesis; 2015 Feb; 36(2):202-11. PubMed ID: 25477341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.
    Patel SA; Longacre TA; Ladabaum U; Lebensohn A; Lin AY; Haraldsdottir S
    Oncologist; 2018 Dec; 23(12):1395-1400. PubMed ID: 30072391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLH1 intronic variants mapping to + 5 position of splice donor sites lead to deleterious effects on RNA splicing.
    Piñero TA; Soukarieh O; Rolain M; Alvarez K; López-Köstner F; Torrezan GT; Carraro DM; De Oliveira Nascimento IL; Bomfim TF; Machado-Lopes TMB; Freitas JC; Toralles MB; Sandes KA; Rossi BM; Junior SA; Meira J; Dominguez-Valentin M; Møller P; Vaccaro CA; Martins A; Pavicic WH
    Fam Cancer; 2020 Oct; 19(4):323-336. PubMed ID: 32363481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome.
    Bouvet D; Bodo S; Munier A; Guillerm E; Bertrand R; Colas C; Duval A; Coulet F; Muleris M
    Gastroenterology; 2019 Aug; 157(2):421-431. PubMed ID: 30998989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of Amino Acid Substitutions in Mismatch Repair Proteins Using PON-MMR2.
    Niroula A; Vihinen M
    Hum Mutat; 2015 Dec; 36(12):1128-34. PubMed ID: 26333163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a germline splice site variant MLH1 c.678-3T>A in a Lynch syndrome family.
    Yang C; Sheehan M; Borras E; Cadoo K; Offit K; Zhang L
    Fam Cancer; 2020 Oct; 19(4):315-322. PubMed ID: 32356167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
    Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
    Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future.
    Rasmussen LJ; Heinen CD; Royer-Pokora B; Drost M; Tavtigian S; Hofstra RM; de Wind N
    Hum Mutat; 2012 Dec; 33(12):1617-25. PubMed ID: 22833534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
    Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
    J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome.
    Gargiulo S; Torrini M; Ollila S; Nasti S; Pastorino L; Cusano R; Bonelli L; Battistuzzi L; Mastracci L; Bruno W; Savarino V; Sciallero S; Borgonovo G; Nyström M; Bianchi-Scarrà G; Mareni C; Ghiorzo P
    Fam Cancer; 2009; 8(4):547-53. PubMed ID: 19728162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.